公司資料
Rezolute 股價、新聞與催化劑
- 股票代碼:
- RZLT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
5.01 USD (-1.57%)
收盤價
最後更新: 2026年8月24日
385M USD
市值
股價為何變動
As of Aug 24, 2026, RZLT closed down 1.57% at $5.01. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Rezolute is a rare-disease and endocrine company focused on hypoglycemia and metabolic disorders. Its programs target difficult hormonal diseases with few effective therapies.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Rezolute sits in specialty biotechnology.
商業模式特徵
The business depends on clinical data, dose strategy, and the chance to build value in rare endocrine disease.
生技產業定位
Rezolute is a small-cap rare-disease catalyst name whose valuation depends on proof-of-concept and execution.
未來催化劑
- Rezolute’s catalyst is ersodetug in hyperinsulinism, where each clinical and regulatory step can materially change the valuation. The market will care about whether the program keeps moving toward a real rare-disease opportunity.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。